Flow cytometric monitoring of the in vitro inhibition of the phosphorylation of CRKL and of SRC family kinases in patients with chronic myelogenous leukemia treated with tyrosine kinase inhibitors

Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F61989592%3A15110%2F15%3A33150317" target="_blank" >RIV/61989592:15110/15:33150317 - isvavai.cz</a>
Alternative codes found
RIV/00098892:_____/15:#0000904
Result on the web
<a href="http://dx.doi.org/10.1111/ijlh.12258" target="_blank" >http://dx.doi.org/10.1111/ijlh.12258</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1111/ijlh.12258" target="_blank" >10.1111/ijlh.12258</a>

Result language
angličtina
Original language name
Flow cytometric monitoring of the in vitro inhibition of the phosphorylation of CRKL and of SRC family kinases in patients with chronic myelogenous leukemia treated with tyrosine kinase inhibitors
Original language description
Sir, Monitoring BCR-ABL1 kinase activity by assaying CRKL phosphorylation (P-CRKL), a technique first introduced by Gorre et al, has proven to be a reliable method for the assessment of the sensitivity and/or resistance of leukemia cells from CML patients to tyrosine kinase inhibitors (TKIs) . In BCR-ABL1-positive cells, P-CRKL is inhibited by TKIs, including imatinib (IM), dasatinib (DAS) and nilotinib (NIL), in a dose-dependent manner. Originally, Western blotting with anti-CRKL antibody was used by several laboratories, including our own, to detect the change in phosphorylation of CRKL. These assays usually involve in vitro analyses of mononuclear cells in which the status of BCR-ABL1 kinase inhibition induced by TKI is measured, or in vivo analysesusing freshly drawn samples. A predictive value was established for the extent of inhibition (e.g., for 50% reduction) of P-CRKL from baseline during a defined time interval of treatment. Later, a flow cytometry method to measure in vivo
Czech name
—
Czech description
—

Type
J<sub>x</sub> - Unclassified - Peer-reviewed scientific article (Jimp, Jsc and Jost)
CEP classification
FD - Oncology and haematology
OECD FORD branch
—

Project
<a href="/en/project/NT12218" target="_blank" >NT12218: Personalized treatment of chronic myeloproliferative disorders and myelodysplastic syndrome - a cellular metabolomics study.</a><br>
Continuities
S - Specificky vyzkum na vysokych skolach

Publication year
2015
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Similar results(10)